mortality
发表于 2025-3-21 18:09:39
书目名称Alternative Approaches to Human Blood Resources in Clinical Practice影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0154037<br><br> <br><br>书目名称Alternative Approaches to Human Blood Resources in Clinical Practice读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0154037<br><br> <br><br>
整理
发表于 2025-3-21 22:08:24
What should Trigger a Transfusion?e similar transfusion demands or transfusion rates. The local practice may be defined by a number of factors, such as the local consensus on the postoperative haemoglobin level or platelet transfusion level, the preferences of opinion leaders in the local clinical community , the availability of
含铁
发表于 2025-3-22 04:13:26
The Efficacy of Technologies to Minimise Peri-Operative Allogeneic Transfusionty of methods intended to minimise peri-operative transfusion. These include pharmacological agents (aprotinin, desmopressin (DDAVP), tranexamic acid (TXA), epsilon aminocaproic acid (EACA) and erythropoietin (EPO)), pre-operative autologous donation (PAD), acute normovolemic haemodilution (ANH), an
harrow
发表于 2025-3-22 04:45:08
Evidence-Based Transfusion Medicine or the Need to Evaluate Clinical Outcome decisions. In practice it means an integration of individual clinical expertise with the best available external clinical evidence from systemic research. EBM will never replace clinical skills, clinical judgement and clinical experience. In the concept of EBM a clinical problem will be turned into
摄取
发表于 2025-3-22 09:19:36
http://reply.papertrans.cn/16/1541/154037/154037_5.png
Confidential
发表于 2025-3-22 16:11:46
http://reply.papertrans.cn/16/1541/154037/154037_6.png
MODE
发表于 2025-3-22 17:49:02
Recombinant Human Erythropoietin — could it be used in a Better Way?pean Union, and Canada since 1993, 1994, and 1996 respectively, and for perisurgical adjuvant therapy without ABD in Canada and the US since 1966. This paper is intended to provide a framework for clinicians who will have the options of administering EPO therapy to patients undergoing surgery, and t
coltish
发表于 2025-3-23 00:44:48
http://reply.papertrans.cn/16/1541/154037/154037_8.png
Muffle
发表于 2025-3-23 03:10:13
The Development of Synthocytes™, a Novel Platelet Substituteomposed of microcapsules of human serum albumin (HSA) to which human fibrinogen is immobilised. The product is manufactured using virally inactivated human blood derived proteins and is formulated as a sterile pyrogen free lyophilised preparation. The potential advantages of Synthocytes. over platel
conjunctiva
发表于 2025-3-23 06:49:25
http://reply.papertrans.cn/16/1541/154037/154037_10.png